Ultrasound contrast developer Acusphere of Watertown, MA, has posted its financial results for the third quarter.
For the period (end-September 30), Acusphere had $667,000 in revenue, which the company attributed to its agreement with Swiss specialty pharmaceutical firm Nycomed for European marketing rights for Imagify, a perfusion stress-echo imaging agent for use in detecting coronary artery disease. The company's net loss after dividends for the third quarter of 2007 was $14.6 million, compared to a net loss of $13.3 million in the prior year's period.
For the first nine months of 2007, Acusphere reported $2 million in revenue, compared to $1.1 million for the same period in 2006.
Acusphere is moving to file a new drug application (NDA) for Imagify with the U.S. Food and Drug Administration.
By AuntMinnie.com staff writers
November 9, 2007
Related Reading
Acusphere releases Imagify study data, November 6, 2007
Acusphere names new CFO, October 4, 2007
Acusphere in 'partnership' discussions, September 20, 2007
Acusphere to raise $20 million, June 13, 2007
Acusphere reports results from Imagify phase III trials, May 4, 2007
Copyright © 2007 AuntMinnie.com
